The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Paul A. Wagner SEE REMARKS | DDisposition to issuer Stock Option (right to buy)derivative | -270,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Paul A. Wagner SEE REMARKS | DDisposition to issuer Stock Option (right to buy)derivative | -500,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Paul A. Wagner SEE REMARKS | DDisposition to issuer Restricted Stock Unitsderivative | -2,500 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Paul A. Wagner SEE REMARKS | DDisposition to issuer Restricted Stock Unitsderivative | -180,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Paul A. Wagner SEE REMARKS | DDisposition to issuer Restricted Stock Unitsderivative | -3,511 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Stephen K Doberstein director | DDisposition to issuer Stock Option (right to buy)derivative | -2,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Stephen K Doberstein director | DDisposition to issuer Stock Option (right to buy)derivative | -1,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Stephen K Doberstein director | DDisposition to issuer Stock Option (right to buy)derivative | -1,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Stephen K Doberstein director | DDisposition to issuer Stock Option (right to buy)derivative | -2,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Stephen K Doberstein director | DDisposition to issuer Stock Option (right to buy)derivative | -31,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Stephen K Doberstein director | DDisposition to issuer Restricted Stock Unitsderivative | -18,353 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -421 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -2,999 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -1,700 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -2,999 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -14,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -323,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -90,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Stock Option (right to buy)derivative | -22,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Restricted Stock Unitsderivative | -750 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Restricted Stock Unitsderivative | -60,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Antony A Riley CHIEF FINANCIAL OFFICER | DDisposition to issuer Restricted Stock Unitsderivative | -2,976 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Richard G Vincent director | DDisposition to issuer Stock Option (right to buy)derivative | -2,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Richard G Vincent director | DDisposition to issuer Stock Option (right to buy)derivative | -31,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Richard G Vincent director | DDisposition to issuer Restricted Stock Unitsderivative | -18,353 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Barbara K Finck director | DDisposition to issuer Stock Option (right to buy)derivative | -2,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Barbara K Finck director | DDisposition to issuer Stock Option (right to buy)]derivative | -166 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Barbara K Finck director | DDisposition to issuer Stock Option (right to buy)derivative | -1,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Barbara K Finck director | DDisposition to issuer Stock Option (right to buy)derivative | -1,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Barbara K Finck director | DDisposition to issuer Stock Option (right to buy)derivative | -7,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Barbara K Finck director | DDisposition to issuer Stock Option (right to buy)derivative | -31,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | Barbara K Finck director | DDisposition to issuer Restricted Stock Unitsderivative | -18,353 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | David W Gryska director | DDisposition to issuer Stock Option (right to buy)derivative | -2,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | David W Gryska director | DDisposition to issuer Stock Option (right to buy)derivative | -1,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | David W Gryska director | DDisposition to issuer Stock Option (right to buy)]derivative | -2,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | David W Gryska director | DDisposition to issuer Stock Option (right to buy)derivative | -31,000 | - | - | 0 | Aug 27, 2026 |
| Aug 27, 2026 | FBRX Forte Biosciences, Inc. | David W Gryska director | DDisposition to issuer Restricted Stock Unitsderivative | -18,353 | - | - | 0 | Aug 27, 2026 |
| Jul 1, 2026 | - FS Credit Real Estate Income Trust, Inc. | Michael C. Forman President & CEO | DDisposition to issuer Class I Restricted Stock Unitsderivativeindirect: Franklin Square Holdings, L.P. | -71,347 | $23.86 | $1.7M | 1,673,355 | Aug 27, 2026 |
| Aug 25, 2026 | AVAT Avalanche Treasury Corp | Robert M Hadick director | DDisposition to issuer Class A Common Stockindirect: By Astral Horizon, L.P. | -237,833 | $0.55 | $130k | 3,762,167 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Tammy M Trent SVP - Chief Accounting Officer | DDisposition to issuer Common Stock | -124,309 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Tammy M Trent SVP - Chief Accounting Officer | DDisposition to issuer Common Stockindirect: Held In Trust Under Issuer's Retirement Plan | -5,861 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Tammy M Trent SVP - Chief Accounting Officer | DDisposition to issuer Common Stockindirect: By Trent Living Trust | -18,773 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Tammy M Trent SVP - Chief Accounting Officer | DDisposition to issuer Cash-Settled Restricted Stock Unitsderivative | -42,048 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Robert S Smith Jr EVP, Pres. - Spec. and FF&T | DDisposition to issuer Common Stock | -291,043 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Robert S Smith Jr EVP, Pres. - Spec. and FF&T | DDisposition to issuer Cash-Settled Restricted Stock Unitsderivative | -139,244 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Lindsey Nicole Odaffer EVP - Chief HR Officer | DDisposition to issuer Common Stock | -150,903 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Lindsey Nicole Odaffer EVP - Chief HR Officer | DDisposition to issuer Common Stockindirect: Held in Trust Under Issuer's Retirement Plan | -25 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Lindsey Nicole Odaffer EVP - Chief HR Officer | DDisposition to issuer Cash-Settled Restricted Stock Unitsderivative | -63,744 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Ryan Michael Kleiboeker EVP-Chief Strategic Plan. Off. | DDisposition to issuer Common Stock | -186,974 | - | - | 0 | Aug 27, 2026 |
| Aug 26, 2026 | LEG LEGGETT & PLATT INC | Ryan Michael Kleiboeker EVP-Chief Strategic Plan. Off. | DDisposition to issuer Common Stockindirect: By Spouse's IRA | -1,000 | - | - | 0 | Aug 27, 2026 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.